- Home
- VNO vs LEGN Comparison
VNO vs LEGN Comparison
Compare VNO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNO | LEGN |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | VNO | LEGN |
|---|---|---|
| Price | $33.73 | $22.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $37.50 | ★ $69.33 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 02-09-2026 | 03-10-2026 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.20 | N/A |
| Revenue | ★ $1,903,939,000.00 | $909,045,000.00 |
| Revenue This Year | N/A | $68.20 |
| Revenue Next Year | $1.18 | $47.77 |
| P/E Ratio | $8.01 | ★ N/A |
| Revenue Growth | 1.75 | ★ 74.75 |
| 52 Week Low | $29.68 | $20.21 |
| 52 Week High | $45.37 | $45.30 |
Technical Indicators
Market Signals| Indicator | VNO | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 42.47 |
| Support Level | $33.23 | $20.21 |
| Resistance Level | $34.62 | $24.12 |
| Average True Range (ATR) | 0.83 | 1.05 |
| MACD | 0.08 | 0.30 |
| Stochastic Oscillator | 44.85 | 47.57 |
Price Performance
Historical ComparisonAbout VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.